Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy

Background: Therapeutic strategies for the prophylaxis of IgE-mediated allergy remain an unmet medical need. Cell therapy is an emerging approach with high potential for preventing and treating immunological diseases. We aimed to develop a cell-based therapy inducing permanent allergen-specific immu...

Full description

Bibliographic Details
Main Authors: Ulrike Baranyi, Andreas M. Farkas, Karin Hock, Benedikt Mahr, Birgit Linhart, Martina Gattringer, Margit Focke-Tejkl, Arnd Petersen, Fritz Wrba, Thomas Rülicke, Rudolf Valenta, Thomas Wekerle
Format: Article
Language:English
Published: Elsevier 2016-05-01
Series:EBioMedicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396416301141
id doaj-c5a057fba16843959d58ec64badd2f2d
record_format Article
spelling doaj-c5a057fba16843959d58ec64badd2f2d2020-11-25T02:19:00ZengElsevierEBioMedicine2352-39642016-05-017C23023910.1016/j.ebiom.2016.03.028Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated AllergyUlrike Baranyi0Andreas M. Farkas1Karin Hock2Benedikt Mahr3Birgit Linhart4Martina Gattringer5Margit Focke-Tejkl6Arnd Petersen7Fritz Wrba8Thomas Rülicke9Rudolf Valenta10Thomas Wekerle11Section of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, AustriaSection of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, AustriaSection of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, AustriaSection of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, AustriaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Physiology and Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaSection of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, AustriaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Physiology and Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaResearch Center Borstel, Clinical and Molecular Allergology, Borstel, GermanyInstitute of Clinical Pathology, Medical University of Vienna, Vienna, AustriaInstitute of Laboratory Animal Science, University of Veterinary Medicine Vienna, Vienna, AustriaDivision of Immunopathology, Department of Pathophysiology and Allergy Research, Center of Physiology and Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, AustriaSection of Transplantation Immunology, Department of Surgery, Medical University of Vienna, Vienna, AustriaBackground: Therapeutic strategies for the prophylaxis of IgE-mediated allergy remain an unmet medical need. Cell therapy is an emerging approach with high potential for preventing and treating immunological diseases. We aimed to develop a cell-based therapy inducing permanent allergen-specific immunological tolerance for preventing IgE-mediated allergy. Methods: Wild-type mice were treated with allergen-expressing bone marrow cells under a short course of tolerogenic immunosuppression (mTOR inhibition and costimulation blockade). Bone marrow was retrieved from a novel transgenic mouse ubiquitously expressing the major grass pollen allergen Phl p 5 as a membrane-anchored protein (BALB/c-Tg[Phlp5-GFP], here mPhl p 5). After transplantation recipients were IgE-sensitized at multiple time points with Phl p 5 and control allergen. Results: Mice treated with mPhl p 5 bone marrow did not develop Phl p 5-specific IgE (or other isotypes) despite repeated administration of the allergen, while mounting and maintaining a strong humoral response towards the control allergen. Notably, Phl p 5-specific T cell responses and allergic airway inflammation were also completely prevented. Interestingly allergen-specific B cell tolerance was maintained independent of Treg functions indicating deletional tolerance as underlying mechanism. Conclusion: This proof-of-concept study demonstrates that allergen-specific immunological tolerance preventing occurrence of allergy can be established through a cell-based therapy employing allergen-expressing leukocytes.http://www.sciencedirect.com/science/article/pii/S2352396416301141Allergy prophylaxisCell-based therapyB-cell toleranceT-cell toleranceAllergen-specific tolerance induction
collection DOAJ
language English
format Article
sources DOAJ
author Ulrike Baranyi
Andreas M. Farkas
Karin Hock
Benedikt Mahr
Birgit Linhart
Martina Gattringer
Margit Focke-Tejkl
Arnd Petersen
Fritz Wrba
Thomas Rülicke
Rudolf Valenta
Thomas Wekerle
spellingShingle Ulrike Baranyi
Andreas M. Farkas
Karin Hock
Benedikt Mahr
Birgit Linhart
Martina Gattringer
Margit Focke-Tejkl
Arnd Petersen
Fritz Wrba
Thomas Rülicke
Rudolf Valenta
Thomas Wekerle
Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy
EBioMedicine
Allergy prophylaxis
Cell-based therapy
B-cell tolerance
T-cell tolerance
Allergen-specific tolerance induction
author_facet Ulrike Baranyi
Andreas M. Farkas
Karin Hock
Benedikt Mahr
Birgit Linhart
Martina Gattringer
Margit Focke-Tejkl
Arnd Petersen
Fritz Wrba
Thomas Rülicke
Rudolf Valenta
Thomas Wekerle
author_sort Ulrike Baranyi
title Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy
title_short Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy
title_full Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy
title_fullStr Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy
title_full_unstemmed Cell Therapy for Prophylactic Tolerance in Immunoglobulin E-mediated Allergy
title_sort cell therapy for prophylactic tolerance in immunoglobulin e-mediated allergy
publisher Elsevier
series EBioMedicine
issn 2352-3964
publishDate 2016-05-01
description Background: Therapeutic strategies for the prophylaxis of IgE-mediated allergy remain an unmet medical need. Cell therapy is an emerging approach with high potential for preventing and treating immunological diseases. We aimed to develop a cell-based therapy inducing permanent allergen-specific immunological tolerance for preventing IgE-mediated allergy. Methods: Wild-type mice were treated with allergen-expressing bone marrow cells under a short course of tolerogenic immunosuppression (mTOR inhibition and costimulation blockade). Bone marrow was retrieved from a novel transgenic mouse ubiquitously expressing the major grass pollen allergen Phl p 5 as a membrane-anchored protein (BALB/c-Tg[Phlp5-GFP], here mPhl p 5). After transplantation recipients were IgE-sensitized at multiple time points with Phl p 5 and control allergen. Results: Mice treated with mPhl p 5 bone marrow did not develop Phl p 5-specific IgE (or other isotypes) despite repeated administration of the allergen, while mounting and maintaining a strong humoral response towards the control allergen. Notably, Phl p 5-specific T cell responses and allergic airway inflammation were also completely prevented. Interestingly allergen-specific B cell tolerance was maintained independent of Treg functions indicating deletional tolerance as underlying mechanism. Conclusion: This proof-of-concept study demonstrates that allergen-specific immunological tolerance preventing occurrence of allergy can be established through a cell-based therapy employing allergen-expressing leukocytes.
topic Allergy prophylaxis
Cell-based therapy
B-cell tolerance
T-cell tolerance
Allergen-specific tolerance induction
url http://www.sciencedirect.com/science/article/pii/S2352396416301141
work_keys_str_mv AT ulrikebaranyi celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT andreasmfarkas celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT karinhock celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT benediktmahr celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT birgitlinhart celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT martinagattringer celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT margitfocketejkl celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT arndpetersen celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT fritzwrba celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT thomasrulicke celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT rudolfvalenta celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
AT thomaswekerle celltherapyforprophylactictoleranceinimmunoglobulinemediatedallergy
_version_ 1724879313513218048